Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
The combination of niacin with a selective
2021-11-23
The combination of niacin with a selective PGD2 receptor antagonist laropiprant, designed to circumvent the flushing side effect of niacin, has been evaluated in the HPS2-THRIVE study and showed no clinically meaningful benefit when administered in patients on top of statin therapy [41]. Our data su
-
GSK 1562590 hydrochloride br The glycine transporter GlyT wa
2021-11-23
The glycine transporter 1 (GlyT1) was originally identified as a member of the solute carrier family 6 of sodium- and chloride-dependent neurotransmitter transporters . GlyT1 is expressed in the central nervous system and in peripheral tissues; mainly in erythroid cells, from erythroblasts in the
-
Acknowledgements This work is partially supported by the Nat
2021-11-23
Acknowledgements This work is partially supported by the Natural Science Foundation of China(81273353), and the National Science & Technology Key Projects of China (2009ZX09103-085). Glyoxalase I (GLO I) is a key enzyme in the pathways leading to glutathione (GSH)-mediated detoxification of meth
-
br Acknowledgements br Introduction Obesity is a growing
2021-11-23
Acknowledgements Introduction Obesity is a growing pandemic, which becomes a global public health problem. The evidence has been readily available and mounting, demonstrating that obesity increases incidences of chronic comorbidities, such as non-alcoholic fatty liver diseases, diabetes, card
-
br Clinical trials testing GLP mimetics in AD or
2021-11-23
Clinical trials testing GLP-1 mimetics in AD or PD patients GIP analogues show good neuroprotective effects in animal models of AD and PD Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino Mdivi 1 incretin growth factor which activates pancreatic islets to enhance insulin secret
-
The presence of ghrelin s mRNA
2021-11-23
The presence of ghrelin's mRNA in the eye and the presence of ghrelin in the aqueous humor, along with a decrease of its levels in glaucoma, suggest a local role for this peptide in the ocular tissue [8], [16], [18]. There is no available data regarding the presence of GHSR-1 in the anterior segment
-
The first GSM was identified from the discovery
2021-11-23
The first GSM was identified from the discovery of non-steroidal anti-inflammatory drugs (NSAIDs). An amyloid reducing GSM that also suppresses inflammation is desirable. Inflammatory response is an invariable characteristic of AD pathogenesis, in part triggered by Aβ. During AD onset and progressio
-
In total strains with relatively rapid acid
2021-11-23
In total, 5 strains with relatively rapid acid-producing ability (MA14, 15M2, DQHXNQ38–12, 5G2, and 6G5) were selected for further analysis. Compared with the strains ATCC19435, ZN8, and D-XJ4–12, which were used as controls, these 5 strains exhibited significantly different growth and titratable ac
-
Patients with SCI often develop chronic neuropathic pain
2021-11-22
Patients with SCI often develop chronic neuropathic pain, which further deteriorates their quality of life [5]. This condition results from functional and structural plastic changes that occur centrally following injury to spinal cord neurons and glia, and include changes in receptor function and si
-
br Discussion Considering cardiovascular risk factors there
2021-11-22
Discussion Considering cardiovascular risk factors, there was a significant difference in prevalence of dyslipidemia in both groups, 57.5% in HIV-infected stroke patients compared to 8.9% in the HIV-uninfected patients. These results are similar to that of Chow et al. who found a dyslipidemia pre
-
A compound structurally similar to PF has been
2021-11-22
A GNE-317 structurally similar to PF-03654746 has been developed by Pfizer (PF-03654764), with a minor change in the substituent attached to the cyclobutanecarboxamide moiety (Wager et al., 2011). This compound, with the chemical name trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2
-
br Acknowledgments br Introduction Guanosine cyclic monophos
2021-11-22
Acknowledgments Introduction Guanosine 3′,5′-cyclic monophosphate (cGMP) is a signaling molecule with key roles in diverse (patho) physiological responses and processes in numerous prokaryotes and all eukaryotes. The number of reports stating the role of cGMP in different processes in plants i
-
The experiments reported herein were designed to test
2021-11-22
The experiments reported herein were designed to test whether co-expression of MRP and GSTP1-1 offers a level of protection from certain cytotoxic drugs not achieved by the expression of either protein alone. This was accomplished by stable transfection with expression vectors into MCF7/WT cells, w
-
Pharmacologic approaches of inhibiting GSNOR activity
2021-11-22
Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
-
br FXR Agonists Azepinol b indole
2021-11-22
FXR Agonists Azepinol[4,5-b]indole 1 (hEC50=600nM, efficacy (eff)=100%) was identified as a FXR agonist lead from a high-throughput screening effort. Structure–activity relationship (SAR) studies around the azepine ring demonstrated that dialkyl substitution at C-1 led to a 30-fold improvement in
14501 records 507/967 page Previous Next First page 上5页 506507508509510 下5页 Last page